The Breast
Volume 19, Issue 6 , Pages 493-498 , December 2010

CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival

  • Ben Davidson

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • The Medical Faculty, University of Oslo, N-0316 Oslo, Norway
    • Corresponding Author InformationCorresponding author at: Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Ullernchausseen 70, Montebello N-0310, Oslo, Norway. Tel.: +47 22934871; fax: +47 22508554.
    • ,
  • Helene Tuft Stavnes

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • ,
  • Mette Førsund

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • ,
  • Aasmund Berner

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • The Medical Faculty, University of Oslo, N-0316 Oslo, Norway
    • ,
  • Anne Cathrine Staff

      Affiliations

    • The Medical Faculty, University of Oslo, N-0316 Oslo, Norway
    • Department of Obstetrics and Gynaecology, Ulleval Hospital, Oslo University Hospital, N-0407 Oslo, Norway

Received 24 February 2010 ,Accepted 24 May 2010.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  3. Fentiman IS, Millis R, Sexton S, Hayword JL. Pleural effusion in breast cancer: a review of 105 cases. Cancer. 1981;47:2087–2092
  4. Raju RN, Kardinal CG. Pleural effusion in breast carcinoma: analysis of 122 cases. Cancer. 1981;48:2524–2527
  5. Wilkes JD, Fidias P, Vaickus L, Perez RP. Malignancy-related pericardial effusion. 127 cases from the Roswell Park Center Institute. Cancer (Phila). 1995;76:1377–1387
  6. Buck M, Ingle JN, Giuliani ER, Gordon JR, Therneau TM. Pericardial effusion in women with breast cancer. Cancer. 1987;60:263–269
  7. Kamby C, Vejborg I, Kristensen B, Olsen LO, Mouridsen HT. Metastatic pattern in recurrent breast cancer. Special reference to intrathoracic recurrences. Cancer. 1988;62:2226–2233
  8. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14:1931–1937
  9. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis. 2008;11:79–89
  10. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005
  11. Staff AC, Braekke K, Johnsen GM, Karumanchi SA, Harsem NK. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol. 2007;197:176.e1–176.e6
  12. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 1999;59:856–861
  13. Dales JP, Garcia S, Bonnier P, Duffaud F, Andrac-Meyer L, Ramuz O, et al. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am J Clin Pathol. 2003;119:374–380
  14. Beresford MJ, Harris AL, Ah-See M, Daley F, Padhani AR, Makris A. The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer. 2006;95:1683–1688
  15. Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, et al. Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination. Clin Cancer Res. 2008;14:2341–2350
  16. Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer. 2000;89:122–126
  17. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001;7:524–532
  18. Vo MN, Evans M, Leitzel K, Ali SM, Wilson M, Demers L, et al. Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy. Breast Cancer Res Treat. 2010;119:767–771
  19. Zhou S, Wang GP, Liu C, Zhou M. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. BMC Cancer. 2006;6:231
  20. Ødegaard E, Davidson B, Engh V, Onsrud M, Staff AC. Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. Am J Obstet Gynecol. 2008;199:533.e1–533.e8
  21. Davidson B, Nielsen S, Christensen J, Asschenfeldt P, Berner A, Risberg B, et al. The role of Desmin and N-cadherin in effusion cytology. A comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol. 2001;25:1405–1412
  22. Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2005;122:33–39
  23. Davidson B, Reich R, Lazarovici P, Flørenes VA, Nielsen S, Nesland JM. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provides the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat. 2004;83:119–128
  24. Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, et al. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients- a novel model for tumor progression. Clin Cancer Res. 2004;10:7335–7346
  25. Elloul S, Bukholt Elstrand M, Nesland JM, Trope CG, Kvalheim G, Goldberg I, et al. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer. 2005;103:1631–1643
  26. Konstantinovsky S, Nielsen S, Vyberg M, Kvalheim G, Nesland JM, Reich R, et al. Angiogenic molecule expression is downregulated in effusions from breast cancer patients. Breast Cancer Res Treat. 2005;94:71–80
  27. Kleinberg L, Flørenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch. 2006;449:31–39
  28. Davidson B, Konstantinovsky S, Kleinberg L, Nguyen MTP, Bassarova A, Kvalheim G, et al. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol. 2006;102:453–461
  29. Kleinberg L, Flørenes VA, Nesland JM, Davidson B. Survivin, a member of the inhibitors of apoptosis (IAP) family, is down-regulated in breast carcinoma effusions. Am J Clin Pathol. 2007;128:389–397
  30. Davidson B, Dong HP, Holth A, Berner A, Risberg B. The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions. Breast J. 2008;14:476–482
  31. Hsu IL, Su WC, Yan JJ, Chang JM, Lai WW. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer. 2009;65:371–376
  32. Duysinx BC, Corhay JL, Hubin L, Nguyen D, Henket M, Louis R. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions. Respir Med. 2008;102:1708–1714
  33. Atanackovic D, Cao Y, Kim JW, Brandl S, Thom I, Faltz C, et al. The local cytokine and chemokine milieu within malignant effusions. Tumour Biol. 2008;29:93–104
  34. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85:178–187
  35. Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax. 1999;54:707–710
  36. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001;193:468–475
  37. Davidson B, Vintman L, Zcharia E, Bedrossian C, Berner A, Nielsen S, et al. Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis. 2004;21:469–476
  38. Cheng D, Lee YC, Rogers JT, Perkett EA, Moyers JP, Rodriguez RM, et al. Vascular endothelial growth factor level correlates with transforming growth factor-beta isoform levels in pleural effusions. Chest. 2000;118:1747–1753
  39. Altomonte M, Montagner R, Fonsatti E, Colizzi F, Cattarossi I, Brasoveanu LI, et al. Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma. Br J Cancer. 1996;74:1586–1591
  40. Henriksen R, Gobl A, Wilander E, Oberg K, Miyazono K, Funa K. Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest. 1995;73:213–220
  41. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res. 1999;5:371–382

PII: S0960-9776(10)00145-1

doi: 10.1016/j.breast.2010.05.013

The Breast
Volume 19, Issue 6 , Pages 493-498 , December 2010

Article Tools

* Image Usage & Resolution